Therapeutic combination of Heberprot-P® and ozone in Venezuelan patients with diabetic foot ulcers
DOI:
https://doi.org/10.5281/zenodo.15046156Keywords:
diabetic foot, complementary therapies, Heberprot-P®, ozone, ulcersAbstract
Introduction: diabetic foot ulcers, a complication of diabetes, present high morbidity and mortality. Heberprot-P® promotes the healing and granulation process of complex ulcer tissue. In recent years, the incorporation of complementary or natural therapies such as ozone has been increasingly used.
Objective: to demonstrate the efficacy of the therapeutic combination of Heberprot-P® and ozone in the management of Venezuelan patients with diabetic foot ulcers.
Method: a therapeutic intervention study was carried out in seven Venezuelan states, with a universe of 1,008 patients and a sample of 822 patients over 18 years of age, from November 2022 to March 2024. The variables analyzed were: age, sex, type of diabetes, Wagner classification, affected limb, granulation time, frequency of attendance at dressings, and surgical interventions. A data collection template was created in Microsoft Office Access and Minitab Statistics for statistical processing. The variables were expressed in absolute and relative frequencies.
Results: patients treated with Heberprot-P® and ozone showed a rapid granulation response (23.96%), within a period of two to four weeks. Surgical interventions were reduced with the combination of both therapies. Only 3.04% of treated patients required reintervention; 5.47% in the Heberprot-P® group and 7.42% in the ozone group.
Conclusions: the therapeutic combination proved to be effective in improving patient quality of life and minimizing the risk of amputation.
Downloads
References
Organización Mundial de la Salud (OMS). Las diez causas principales de defunción. OMS; 2024 [consultado 28 Mar 2024]. Disponible en: https://www.who.int/es/news-room/fact-sheets/detail/the-top-10-causes-of-death
Magliano DJ, Boyko EJ; Comité científico del Atlas de Diabetes de la FID, 10.ª edición. ATLAS DE DIABETES DE LA FID [Internet]. 10.ª edición. Bruselas: Federación Internacional de Diabetes; 2021. Disponible en: https://www-ncbi-nlm-nih-gov.translate.goog/books/NBK581934/?_x_tr_sl=en&_x_tr_tl=es&_x_tr_hl=es&_x_tr_pto=tc
Armstrong DG, Swerdlow MA, Armstrong AA, Conte MS, Padula WV, Bus SA. Five year mortality and direct costs of care for people with diabetic foot complications are comparable to cancer. J Foot Ankle Res [Internet]. 2020 [citado 18 Dic 2024]; 13(1):16. DOI: https://doi.org/10.1186/s13047-020-00383-2
Ministerio del Poder Popular para la Salud (MPPS). República Bolivariana de Venezuela. Anuario de Mortalidad 2016 [Internet]. 2017 [consultado 8 Abr 2022]. Disponible en: http://www.ucv.ve/fileadmin/user_upload/cendes/textos_completos/ANUARIO_MORTALIDAD_2016.pdf
Orellano P, Sánchez L, Introini L, Torre W, Torres Negrerira M, Cabrera M, et al. Costos directos en el tratamiento del pie diabético Unidad de Pie Diabético. Hospital de Clínicas. Universidad de la República. Rev Méd Uruguay [Internet]. 2023 [citado 18 Dic 2024]; 39(4):e202. Disponible en: http://www.scielo.edu.uy/scielo.php?pid=S1688-03902023000401202&script=sci_arttext
Dean Barbosa Marqués A, Soles da Silva MM, Magalhaes Moreira TM. Association between hospitalization due to diabetes mellitus and diabetic foot amputation. Rev Enferm. glob. [Internet]. 2018 [citado Ene 2025]; 17(51). DOI: https://dx.doi.org/10.6018/eglobal.17.3.286181
González Cedeño M, Alfonseca Guerra M, Hernández Rodríguez M. Enfoque social del manejo de pie diabético desde la atención primaria de salud. Rev Hum Méd [Internet]. 2022 [citado 5 Ene 2025]; 22(2). Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1727-81202022000200421
Castillo Deprés S, Geoffrey Mothabeng T, Ledwaba L, Ngcobo TK, Singh N, Baldomero Hernández JE, et al. Heberprot-P en el tratamiento de las úlceras del pie diabético. Rev Cub Med Mil [Internet]. 2022 Sep [citado 22 Ene 2025]; 51(3). Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0138-65572022000300028&lng=es
Berlanga-Acosta J, Garcia-Ojalvo A, Guillén-Nieto G, Ayala-Avila M. Endogenous biological drivers in diabetic lower limb wounds recurrence: hypothetical reflections. Inter J Molecular Scien [Internet]. 2023 [citado 28 Ene 2025]; 24(12). DOI: https://doi.org/10.3390/ijms241210170
Pasek, S Szajkowski, G Cieślar. Effect of Treatment of Neuropathic and Ischemic Diabetic Foot Ulcers with the Use of Local Ozone Therapy Procedures—An Observational Single Center Study. Clin Pract [Internet]. 2024 [citado 28 Ene 2025];14(5):2139-2150. DOI: https://doi.org/10.3390/clinpract14050169
Fabelo Martínez A, Figueroa Martínez A, Valdés Pérez C, Pérez Leonard D, Álvarez López A. Evolución de las úlceras de pie diabético con el tratamiento mixto de Heberprot-P® y ozonoterapia. Rev Cubana Angiol Cir Vasc [Internet]. 2019 [citado 8 Dic 2024]; 20(1):e378. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1682-00372019000100003
García Herrera AL, García Moliner AL, Castaneiras Jorge E, Febles Sanabria R. Efectividad de diferentes métodos de planimetría aritmética para la mensuración de úlceras del pie diabético. Rev Cubana Angiol Cir Vasc [Internet] 2023 [citado 14 Jun 2024]; 24(1). Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1682-00372023000100005
Escobar Amarales Y, Torres Romo UR, Escalante Padrón O, Fernández Franch N, Ibarra Viena l, Miranda Rodríguez E. El Heberprot-P® en el tratamiento de úlceras del pie diabético. AMC [Internet]. 2014 [citado 8 Sep 2024]; 18(3):297-308. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1025-02552014000300005
Verdaguer Pérez L, Muguercia Silva JL, Ayala Lafargue D, Bertrán Bahades J, Estrada Ladoy L. Experiencias en el tratamiento con Heberprot-P® en pacientes con pie diabético. Medisan [Internet]. 2017 [citado 9 Mayo 2024]; 21(8):993-999. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1029-30192017000800005
Miranda Pedroso R, González Tapia M, Monzón Tamargo MJ, Pozo Pozo D. Uso del Heberprot-P 75 en paciente con Pie diabético Grado 3. Rev Ciencias Médicas [Internet]. 2019 [citado 8 Sep 2024]; 23(2):351-5. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1561-31942019000200351
Texeira Costa WJ, Abreu LC. Prevalence of diabetic foot and its risk factors in the State of Espirito Santo, Brazil. Rev J Hum Grow Develop [Internet]. 2024 [citado 8 Ene 2025];33(1). DOI: https://doi.org/10.36311/jhgd.v33.14295
Silva Pupo M, González Moya IA, Valenciano García Y, González Cedeño M. Evolución de lesiones complejas en el pie diabético con uso de Heberprot-P®. AMC [Internet]. 2015 [citado 18 Ene 2025]; 19(4) Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1025-02552015000400007
Turner Maxime J, Van Vuuren S, Leigh-de Rapper S. Analysing patient factors and treatment impact on diabetic foot ulcers in South Africa. Rev South Afr J Sci [Internet]. 2024 [citado 8 Ene 2025]; 120(3/4):16301. DOI: https://doi.org/10.17159/sajs.2024/16301
Mehraj M, Shah I. A review of Wagner classification and current concepts in management of diabetic foot. Rev Inter J Orthop Sci [Internet]. 2018. [citado 8 Ene 2025]; 4(1):933-935. Disponible en: https://www.orthopaper.com/archives/2018/vol4issue1/PartN/4-1-111-634.pdf
Jaroslaw P, Szajkowski S, Cieslar G. Effect of Treatment of Neuropathic and Ischemic Diabetic Foot Ulcers with the Use of Local Ozone Therapy Procedures-An Observational Single Center Study. Rev Clin Pract. [Internet]. 2024 [citado 28 Ene 2025]; 14(5):2139-2150. DOI: https://doi.org/10.3390/clinpract14050169
Oliveira Martines LO, Vieira da Silva Neto P, Vanina Ortiz J. Heberprot-P® and ozone therapy in the treatment of diabetic foot ulcers: a bibliographic review. RSD [Internet]. 2021 [citado 28 Ene 2025]; 10(15). DOI: https://doi.org/10.33448/rsd-v10i15.22952
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Tatiana González Estévez, Aymara Laugart Wilson, Daylin Elizabeth González García, Hansel Frómeta Hernández, Juliana Yasmin Pacheco Godoy
This work is licensed under a Creative Commons Attribution 4.0 International License.
